Innovative Medical Technology ANEUVO specializes in non-invasive neuromodulation systems like ExaStim®, which has received CE Mark approval and FDA Breakthrough Device Designation, indicating a strong position in advanced medical device development and regulatory progress.

Expanding Clinical Scope The company is actively conducting US clinical studies for ExaStim® targeting paralysis from spinal cord injuries, presenting opportunities to collaborate with healthcare providers and research institutions involved in neurorehabilitation.

Geographic Market Focus While ExaStim® is approved in Europe and used in demonstrations, its restricted investigational status in the US suggests potential for partnerships to accelerate commercial approval and distribution in North America.

Funding and Revenue Potential With revenue estimates between 1 million to 10 million dollars and ongoing product development, there is significant growth potential for sales efforts focusing on hospitals and specialized neurorehabilitation centers.

Industry Engagement Participation in major industry events like RehaCare 2025 and ISCoS 2025 demonstrates active engagement with key stakeholders, offering sales development opportunities through event outreach and strategic partnerships.